Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status-Reference-Cited by-同舟云学术

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

Published:2017-07-24 Issue:2 Volume:32 Page:450-461
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kubesova B,Pavlova S,Malcikova J,Kabathova J,Radova L,Tom N,Tichy B,Plevova K,Kantorova B,Fiedorova K,Slavikova M,Bystry V,Kissova J,Gisslinger B,Gisslinger H,Penka M,Mayer J,Kralovics R,Pospisilova S,Doubek M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017230.pdf

Reference55 articles.

1. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664–2670.

2. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD . Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29: 3907–3913.

3. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441–447.

4. Sterkers Y, Preudhomme C, Laï JL, Demory JL, Caulier MT, Wattel E et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616–622.

5. Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29: 2410–2415.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single‐cell RNA sequencing;Molecular Oncology;2024-05-21

2. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1‐negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia‐related;International Journal of Laboratory Hematology;2024-04-26

3. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms;Blood Cancer Journal;2024-01-04

4. Molecular diagnostic criteria of myeloproliferative neoplasms;Expert Review of Molecular Diagnostics;2023-11-24

5. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis;American Journal of Hematology;2023-10-17